<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282227</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2017-001</org_study_id>
    <nct_id>NCT03282227</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine</brief_title>
  <acronym>ADAM</acronym>
  <official_title>A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, twelve-month safety study. There is a screening period followed by a
      run-in period to record migraine activity. Qualified subjects will receive study medication
      for up to twelve months for the treatment of multiple migraine attacks. Using the eDiary to
      confirm they are experiencing a qualified migraine, subjects will self-administer the patches
      and respond to questions in the eDiary post treatment administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, twelve-month safety study. There is a screening period followed by a
      run-in period (14 to 21 days) to determine eligibility for treatment with study medication
      based on daily eDiary data collection. Qualified subjects will receive study medication on
      Day 1 for up to twelve months for the treatment of migraine headaches. Migraines will be
      treated with a single dose, consisting of two patches, but subjects can treat multiple
      migraine attacks throughout the 12 months. Using the eDiary to confirm they are experiencing
      a qualified migraine, subjects will self-administer the patches and continue to respond to
      questions in the eDiary for 48 hours post treatment administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single dose, open-label treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety as measured by incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term safety as measured by incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with pain freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with pain freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with most bothersome symptom freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with freedom from most bothersome symptom other than pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with pain relief</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with pain relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with nausea freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with nausea freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with photophobia freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with photophobia freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with phonophobia freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with phonophobia freedom</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>M207 Microneedle System 3.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M207 Microneedle System</intervention_name>
    <description>M207 Microneedle System 3.8 mg</description>
    <arm_group_label>M207 Microneedle System 3.8 mg</arm_group_label>
    <other_name>ZP-Zolmitriptan Intracutaneous Microneedle System</other_name>
    <other_name>ADAM-Zolmitriptan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Women or men 18 to 75 years of age

          2. Greater than 1 year history of episodic, migraine (with or without aura) with onset
             prior to 50 years of age.

          3. Migraine history during the prior 6 months must include:

               1. at least 2 migraines per month

               2. no more than 8 migraines per month

               3. no more than 15 headache days per month

          4. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy
             and use an acceptable double-barrier method of birth control during the trial.

          5. Willing and able to treat a minimum of 2 migraines per month with study medication and
             consistently complete eDiary for up to 12 months.

        Main Exclusion Criteria:

          1. Contraindication to triptans

          2. Use of SSRIs (drugs like Prozac®) or SNRIs (drugs like Effexor®) or anti-coagulants
             (drugs like Coumadin®)

          3. Known allergy or sensitivity to zolmitriptan or its derivatives or formulations

          4. Known allergy or sensitivity to adhesives and/or titanium

          5. Women who are pregnant, breast-feeding or plan a pregnancy during this study

          6. Three or more of the following cardiovascular risk factors:

               -  Current tobacco use

               -  Hypertension or receiving anti-hypertensive medication for hypertension

               -  Hyperlipidemia or on prescribed anti-cholesterol treatment

               -  Family history of premature coronary artery disease

               -  Diabetes mellitus

          7. History or current abuse or dependence on alcohol or drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Whitney Halladay</last_name>
    <phone>510-745-4011</phone>
    <email>whalladay@zosanopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pete Schmidt, MD</last_name>
    <phone>510-745-1251</phone>
    <email>pschmidt@zosanopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Moya</last_name>
      <email>cmoya@accelclinical.com</email>
    </contact>
    <investigator>
      <last_name>Hayes Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolie Brooks</last_name>
      <email>jolie@eliteclinicalstudies.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Lillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Cisneros</last_name>
      <email>ccisneros@dtlaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Salil Nadkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Hartley</last_name>
      <email>jakemh@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Nada Hindiyeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Associates of Santa Clara Valley Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Annecone</last_name>
      <email>kma@allergycare.com</email>
    </contact>
    <investigator>
      <last_name>James Wolfe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Neyman</last_name>
      <email>tneyman@drkudrow.com</email>
    </contact>
    <investigator>
      <last_name>David Kudrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Castillo</last_name>
      <email>ccastillo@empireclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Gordon</last_name>
      <email>sgordon@empireclinicalresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amit Paliwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Benton</last_name>
      <email>rachelb@coloradoallergy.com</email>
    </contact>
    <investigator>
      <last_name>Shaila Gogate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harmony Medical Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisset Delgado</last_name>
      <email>ldelgado@hmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Juan Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Smith</last_name>
      <email>fsmith@acr-research.com</email>
    </contact>
    <investigator>
      <last_name>Mark Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler Hastings</last_name>
      <email>thastings@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Dennis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Axelrod</last_name>
      <email>bct@bostontrials.com</email>
    </contact>
    <investigator>
      <last_name>Robert Barger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silpa Mohapatra</last_name>
      <email>mohapatra@medvadis.com</email>
    </contact>
    <investigator>
      <last_name>Egilius Spierings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Headache and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Babcock</last_name>
      <email>jbabcock@mhni.com</email>
    </contact>
    <investigator>
      <last_name>Joel Saper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Radtke</last_name>
      <email>ryan.radtke@criminnesota.com</email>
    </contact>
    <investigator>
      <last_name>Gary Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla McBrady</last_name>
      <email>karla.mcbrady@CRIminnesota.com</email>
    </contact>
    <investigator>
      <last_name>Hemalini Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303-3041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Straatmann</last_name>
      <phone>636-387-5100</phone>
      <email>dstraatmann@studymetrix.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Nalley</last_name>
      <email>knalley@clinvest.com</email>
    </contact>
    <investigator>
      <last_name>David True, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Ellis</last_name>
      <email>tara.a.ellis@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Stewart Tepper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hsi</last_name>
      <email>dhsi@abqct.com</email>
    </contact>
    <investigator>
      <last_name>Marigene Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie O'Reilly</last_name>
      <email>joreilly@rcrclinical.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Meris</last_name>
      <email>wendym@petersmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Jarrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Williamson</last_name>
      <email>lwilliamson@nccr.com</email>
    </contact>
    <investigator>
      <last_name>Craig LaForce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raleigh Medical Group PMG Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Gillis</last_name>
      <email>kelsey.gillis@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>John Rubino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lillestol Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Peterson</last_name>
      <email>kpeterson@lillestolresearch.com</email>
    </contact>
    <investigator>
      <last_name>Michael Lillestol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hopkins</last_name>
      <email>mary.hopkins@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Nahas-Geiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Care Associates/Radiant Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Harrison</last_name>
      <email>kristina.harrison@synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Erin Cooksey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Willey</last_name>
      <email>swilley@coastalcarolinaresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Nelson</last_name>
      <email>dnelson@coastalcarolinaresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Strout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Ford</last_name>
      <email>kevinf@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>John Hudson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Neurology Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Fehmel</last_name>
      <email>jennifer.fehmel@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shealynn Korpi</last_name>
      <email>skorpi@ctxhr.com</email>
    </contact>
    <investigator>
      <last_name>Frank Hampel Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>migraine headache</keyword>
  <keyword>acute migraine</keyword>
  <keyword>acute migraine headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

